Bovine serum albumin-bound homologous targeted nanoparticles for breast cancer combinatorial therapy.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7909578 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-0003 (Electronic) Linking ISSN: 01418130 NLM ISO Abbreviation: Int J Biol Macromol Subsets: MEDLINE
    • Publication Information:
      Publication: Amsterdam : Elsevier
      Original Publication: Guildford, Eng., IPC Science and Technology Press.
    • Subject Terms:
      Serum Albumin, Bovine*/chemistry ; Breast Neoplasms*/drug therapy ; Breast Neoplasms*/pathology ; Breast Neoplasms*/metabolism ; Nanoparticles*/chemistry ; Copper*/chemistry ; Copper*/pharmacology ; Chlorophyllides* ; Photochemotherapy*/methods; Animals ; Female ; Humans ; Mice ; Porphyrins/chemistry ; Porphyrins/pharmacology ; Cell Line, Tumor ; Apoptosis/drug effects ; Photosensitizing Agents/pharmacology ; Photosensitizing Agents/chemistry ; Cattle ; Xenograft Model Antitumor Assays
    • Abstract:
      Breast cancer, the most common lethal cancer among women, is characterized by the uncontrolled growth of abnormal cells in breast tissue. Therefore, synergistic anticancer strategies are essential, particularly for maximizing drug delivery to tumor sites. Herein, bovine serum albumin (BSA)-bound nanoparticles encapsulating the photosensitizer chlorin e6 (Ce6) (BC) with a CuO 2 core (BC/CuO 2 NPs) were developed for cuproptosis-promoted cancer photodynamic therapy (PDT). The cancer cell membrane (CC) was then coated onto the surfaces to produce BC/CuO 2 @CC NPs for breast cancer combinatorial therapy. BSA serves dual functions as both a stabilizing scaffold for metal peroxide nanomaterials and a molecular connector for Ce6. The BC/CuO 2 @CC NPs group showed the stronger internalization capability than the other groups. BC/CuO 2 @CC NPs could effectively induce the greatest degree of apoptosis and death ratio (81.77 %), and lead to cuproptosis by downregulating the expression of DLAT, LIAS, and FDX1 protein in vitro. The intra-tumoral accumulation of BC/CuO 2 @CC NPs was 8.3- and 7.7-fold higher than that of Ce6 and BC/CuO 2 @CC NPs at 24 h postinjection, respectively. Moreover, synergistic efficacy of cuproptosis and PDT not only inhibited tumor growth but also prevented liver metastases. Thus, our work may be a novel approach for efficient and targeted cancer treatment.
      Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
      (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
    • Contributed Indexing:
      Keywords: Biomimetic nanoparticles; Cuproptosis; Photodynamic therapy
    • Accession Number:
      27432CM55Q (Serum Albumin, Bovine)
      789U1901C5 (Copper)
      5S2CCF3T1Z (phytochlorin)
      0 (Chlorophyllides)
      0 (Porphyrins)
      0 (Photosensitizing Agents)
      V1XJQ704R4 (cupric oxide)
    • Publication Date:
      Date Created: 20240929 Date Completed: 20241116 Latest Revision: 20241116
    • Publication Date:
      20241118
    • Accession Number:
      10.1016/j.ijbiomac.2024.136090
    • Accession Number:
      39343270